Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Cephalon |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00469209 |
Primary Objectives:
Condition | Intervention | Phase |
---|---|---|
Myeloma |
Drug: Trisenox (Arsenic Trioxide) Drug: Velcade (Bortezomib) Drug: Melphalan Drug: Vitamin C (Ascorbic Acid) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma |
Ages Eligible for Study: | up to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
U.T.M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Muzaffar H. Qazilbash, MD | U.T.M.D. Anderson Cancer Center |
Study ID Numbers: | 2005-0893 |
Study First Received: | May 3, 2007 |
Last Updated: | September 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00469209 |
Health Authority: | United States: Institutional Review Board |
Multiple Myeloma Melphalan Trisenox Arsenic Trioxide |
Ascorbic Acid Vitamin C Velcade Bortezomib |
Melphalan Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Bortezomib Vascular Diseases Arsenic trioxide |
Paraproteinemias Hemostatic Disorders Multiple Myeloma Hemorrhagic Disorders Multiple myeloma Lymphoproliferative Disorders Ascorbic Acid Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Antioxidants Immunologic Factors Immune System Diseases Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Immunosuppressive Agents Protective Agents |
Pharmacologic Actions Protease Inhibitors Neoplasms Therapeutic Uses Vitamins Myeloablative Agonists Cardiovascular Diseases Antineoplastic Agents, Alkylating Micronutrients Alkylating Agents |